ArticleBMC cancer2026
Upregulation of miR-32 in tissue and plasma and its association with PTEN expression in colorectal cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEarly detection of colorectal cancer (CRC) is critical for improving patient outcomes. MicroRNAs (miRNAs) function as post-transcriptional regulators and have emerged as potential minimally invasive diagnostic biomarkers. Although miR-32 has been implicated in tumor progression in several malignancies, its expression pattern in CRC tissue and plasma and its association with PTEN expression require further clarification. MATERIALS AND
methodsExpression levels of miR-32 and PTEN were measured using quantitative real-time PCR (qRT-PCR) in tumor tissues, adjacent normal tissues, and plasma samples from 55 CRC patients and plasma samples from 55 age and sex matched healthy controls.
resultsMiR-32 expression was significantly upregulated in CRC tissues and plasma samples, whereas PTEN expression was significantly reduced in tumor tissues (P < 0.001). ROC curve analysis demonstrated strong diagnostic performance of miR-32 in tissue (AUC = 0.942) and good performance in plasma (AUC = 0.846). An inverse association between miR-32 and PTEN expression was observed. Higher miR-32 levels were also associated with advanced tumor stage.
conclusionsThis is the first report of concurrent miR-32 upregulation and PTEN downregulation in both CRC tissue and plasma. MiR-32 may represent a potential non-invasive biomarker candidate for CRC detection and disease stratification. However, these findings are observational and require validation in larger, multicenter cohorts and functional studies before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.